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ABSTRACT
OBJECTIVES: This study examined the purchases of eculizumab, a high-cost monoclonal 
antibody used in the treatment of rare diseases by Brazilian federal agencies, in terms of 
purchased quantities, expenditures, and prices.
METHODS: Eculizumab purchases made between March 2007 and December 2018 were 
analyzed, using secondary data extracted from the Federal Government Purchasing System 
(SIASG in Portuguese). The following aspects were assessed: number of purchases, purchased 
quantities, number of daily doses defined per 1,000 inhabitants per year, annual expenditures, 
and prices. The prices were adjusted by the National Broad Consumer Price Index for December 
2018. Linear regression was used for trend analysis.
RESULTS: All acquisitions by federal agencies were made by the Brazilian Ministry of Health. 
The purchases began in 2009 with tender waiver to comply with legal demand. There was an 
increasing trend in the number of purchases and quantities acquired over time. Two hundred 
and eighty-three purchases were made, totaling 116,792 units purchased, 28.2% of them in 
2018. The adjusted total expenses summed more than R$ 2.44 billion. After market approval 
by the Brazilian Health Regulatory Agency, the weighted average price fell approximately 35%, 
to values under the Medicines Market Chamber of Regulation established prices.
CONCLUSION: Eculizumab represented extremely significant expenditures for the Brazilian 
Ministry of Health during the period. All purchases were made to meet demands from 
lawsuits, outside the competitive environment. The market approval of eculizumab promoted 
an important price reduction. This study indicates the relevance of licensing and the need for 
permanent monitoring and auditing of drug purchases to meet legal demands. 
DESCRIPTORS: Hemoglobinuria, Paroxysmal, drug therapy. Drug Costs. Orphan Drug 
Production, legislation & jurisprudence. Health’s Judicialization. Public Expenditures on Health. 
National Drug Policy.
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INTRODUCTION
Eculizumab is a high-cost drug indicated to ease adult and pediatric patients’ 
complications with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic 
uremic syndrome (aHUS). The PHN is an acquired disorder of hematopoietic stem 
cells, which is characterized by a highly variable clinical course, including hemolytic 
anemia, bone marrow failure, and thromboembolic phenomena, with complement-
mediated manifestations1. The aHUS is a clinical entity marked by the presence of 
thrombocytopenia, microangiopathic hemolytic anemia, and progressive kidney damage, 
resulting from mutations in genes that control the complement system2.
Both are considered rare diseases because they affect up to 65 people in 100,000 individuals3. 
Clinically significant PNH affects one to ten individuals per one million, although this 
number may be underestimated as some patients may remain undiagnosed because of the 
heterogeneous spectrum of clinical manifestations and diagnostic difficulties4,5. The aHUS 
frequency is also low, even though it is difficult to determine its exact incidence6. In Brazil, 
the prevalence of the two conditions is unknown7.
Eculizumab is a humanized monoclonal antibody that blocks the activation of the terminal 
complement C5 and prevents the formation of Complement Component 5a (C5a) and C5b-9, 
reducing the need for blood transfusions and the thrombolysis risk8. The drug was registered 
to PNH in the U.S. Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) in 2007, with a record interval of just three months. In both cases, the 
approval happened because of prerogatives regarding the so-called “orphan drugs” based 
on small clinical trials9,10. The PNH registration in Canadian and Japanese health agencies 
was obtained, respectively, in 2009 and 2010.
In Brazil, market approval was only asked by the manufacturer (Alexion Pharmaceuticals 
Inc.) in March 2015, being granted by the Brazilian Health Regulatory Agency (ANVISA) 
on March 13, 201711. The price was established by the Brazilian Chamber of Drug 
Market Regulation (CMED) in October 2017, with maximum retail selling price to the 
government (PMVG), which corresponds to the price ceiling for any drug purchased by 
judicial decision, set at R$ 13,614.80 (with 0% Brazilian state excise tax) per 300 mg viala. 
The treatment of an adult with PNH at the dose defined in the leaf let would correspond 
to the use of 74 vials in the first treatment year and then 72 vials/year in the second year 
and onwards, for life. According to data from the Brazilian Federal Attorney General’s 
Office (AGU), spending on health litigation within the Union totaled more than R$ 
1.325 billion in 2016, representing an increase of more than 5,000% compared to the 
R$ 26 million spent in 2007. Eculizumab has been litigated in Brazil for several years 
and this modality has provided 100% of the public provision. In 2016 alone, eculizumab 
legal purchases totaled R$ 624,621,563.43, representing the main item of expenditures 
and 41.2% of the resources involved in drug litigation12.
In 2018, the Secretariat of Science, Technology and Strategic Inputs (SCTIE) of the Brazilian 
Ministry of Health (MS) submitted a request for the incorporation of eculizumab to the 
National Committee for Health Technology Incorporation of the Brazilian Unified Health 
System (Conitec). The drug was assessed and incorporated only for the PNH treatment, 
from the publication no. 77, of December 14, 201813.
The drug’s high costs, its significant participation in expenses with health litigation, 
its economic impact on the Brazilian Ministry of Health expenditures, and the factors 
involved in its market approval, price, and incorporation by the Brazilian Unified Health 
System (SUS) highlight the importance of studying the eculizumab purchases made 
by federal agencies from 2007 to 2018, in terms of quantities purchased, expenditures, 
and prices.
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METHODS
This is an exploratory study with a quantitative approach, focusing on the purchases of 
eculizumab performed by agencies of the federal public administration from January 2007 
to December 2018. The choice of time interval intended to consider the year of the initial 
market approval by the health agencies of the United States and Europe, until 2018, when 
the drug was already licensed in Brazil and had its prices established by CMED.
The following data were extracted from the records of the Federal Government Purchasing 
System (SIASG), controlled by the Brazilian Ministry of Planning, Budget and Management 
(MP): number of purchases, quantities purchased, type of acquisition, federal agency 
responsible for the purchases, contracted supplier, unit prices, amounts of contracted 
expenditures, and justifications for purchases during each year of the period.
To enable comparability between the years, the unit acquisition prices extracted from 
SIASG were adjusted for December 2018, applying the annual variation of the National 
Consumer Price Index (IPCA), according to Law no. 10,742 of 2003, which defined this index 
for adjustment in drug prices in Brazil14.
In order to assess the historical behavior of drug purchases, trend analyses were performed 
using linear regression.
Eculizumab purchases can be understood as a proxy for utilization, in this case, 
consumption. For this analysis, two estimates were made. The number of people 
potentially treated per year was estimated by dividing the number of 300 mg vials 
purchased by the number of required vials to treat an adult patient per year (72 vials). 
The defined daily dose (DDD) was also used, an international measure of consumption 
recommended by the World Health Organization, which is not strictly related to the actual 
dose and represents the average dose for a 70 kg adult patient15. The DDD standardization 
allows comparability. For population estimates, this indicator is parameterized as the 
number of DDD/1,000 inhabitants/day; in this case, it was considered appropriate to 
present the number of DDD/1,000 inhabitants/year16. Data from the Brazilian population 
in the study years were obtained from the Brazilian Institute of Geography and 
Statistics (IBGE)17.
All data obtained from SIASG were compiled to a database specifically built for this purpose, 
and statistical calculations, including trend analyses, were performed using the Microsoft 
Excel software.
Table 1. Number of federal purchases and of dosage forms of eculizumab (300mg vial), 2009–2018.
Year
Number  
of purchases
Number of dosage forms acquired
Quantity % Total
2009 2 145 0.12
2010 4 180 0.15
2011 12 754 0.65
2012 16 2,166 1.85
2013 69 8,296 7.10
2014 50 14,061 12.04
2015 57 19,206 16.44
2016 54 25,386 21.74
2017 4 13,721 11.75
2018 15 32,877 28.15
Total 283 116,792 100.00
Note: There were no federal purchases in 2017 and 2018.
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Access to  SIASG data is public, in accordance with the Brazilian Access to Information 
Act; thus, not requiring the prior submission of the study to a research ethics committee.
RESULTS
The mapping of the drug purchases within SIASG showed that the first eculizumab 
acquisitions occurred in February 2009, two years after the first international market 
approval license was issued. In the period, all federal eculizumab purchases were performed 
by the Department of Logistics in Health of the Brazilian Ministry of Health, all exempt 
from bidding and always with the justification of compliance with legal demands.
The number of purchases and quantities acquired over time showed an increasing trend. 
Twenty-eight purchases were made in the period, totaling 116,792 vials, 28.2% of which were 
purchased in 2018 (Table 1). It is also observed that 2017 experienced a significant drop in 
the number of purchases and in number of purchased dosage forms (13,721).
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Figure 1. Estimates of number of treated patients per year and number of DDDs per 1.000 inhabitants/
year in federal eculizumab purchases. 2009–2018.
Table 2. Expenses contracted in current and adjusted values regarding federal eculizumab purchases 
(300 mg vial), 2009–2018.
Year
Contracted expenses current 
amounts (R$)
Adjusted contract  
expenses (R$)
% adjusted total 
expenses
2009 2,219,023.25 3,924,941.63 0.16
2010 2,366,823.72 4,000,091.69 0.16
2011 8,979,795.84 14,330,935.34 0.59
2012 28,783,166.97 43,131,746.38 1.76
2013 125,450,088.18 177,631,768.91 7.27
2014 213,729,757.88 285,742,220.30 11.69
2015 376,945,601.92 473,604,100.41 19.38
2016 624,621,376.84 709,126,486.07 29.02
2017 267,111,457.23 285,303,416.91 11.67
2018 447,156,839.74 447,156,839.74 18.30
Total 2,097,363,931.57 2,443,952,547.39 100.00
a Prices were adjusted by the National Broad Consumer Price Index for December 2018
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Figure 1 shows the relationship between the number of dosage forms acquired for potentially 
treated patients and the number of DDD/1,000 inhabitants/year, verifying proportionality 
and progressive trend increase of both over time.
The expenses between 2009 and 2018 totaled R$ 2.1 billion in current values and R$ 2.44 
billion in adjusted value by the December 2018 IPCA (Table 2). Despite accounting for more 
than a quarter of all dosage forms acquired in the period, 2018 corresponded to only 18.3% 
of the expenditures in the interval studied (Figure 2).
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Figure 2. Proportions of units acquired and total expenses adjusted with the eculizumab drug in federal 
purchases during the period 2009–2018. second year of purchase.
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Figure 3. Adjusted weighted average price (in R$) practiced in federal eculizumab purchases (300 mg 
vial). 2009-2018.
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Until registration in 2017, there was a great variation in the weighted average price (WAP) 
paid per dosage form, which reached R$ 27,933.76 in 2016 (Figure 3). The two purchases made 
before obtaining market approval at ANVISA in 2017 (10,733 units, 78% of the total purchased 
in the year) presented a R$ 21,055.61 WAP in current values. The two acquisitions made 
after market approval and after the setting of the maximum selling price to the government 
(totaling 2,988 vials) presented a lower WAP (R$ 13,515.01) than the one established by the 
CMED in October 2017 (R$ 13,614.90), showing an important impact on price reduction 
(-35.8%). All purchases in 2018 presented a lower WAP (R$ 13,600.90) than the amount per 
vial defined by CMED in April 2018 (R$ 13,889.35).
DISCUSSION
Eculizumab has been frequently mentioned in the pages of newspapers and media venues 
in recent years. The drug has already been described as the most expensive in the world, 
with an approximate cost of $410,000 per patient/year in the U.S. in 201018. In Brazil, the 
cost of treating a single patient per year, who obtained treatment via legal means, exceeded 
R$ 800,000 in 201219.
Since 2009, eculizumab has been bought in the country in great quantities and its 
expenditures show a growing trend over time. However, 2017 presented an important drop 
in the number of purchases (from more than 50 purchases in the previous three years to 
only four in that year) and in purchased dosage forms (a -49.5% reduction when compared 
to the quantity acquired in 2016). The data available in SIASG do not allow the study to 
expand the understanding of this abrupt decline, but two facts may have contributed. 
In 2017, the Brazilian Federal Police launched the Operação Cálice de Hígia (Operation 
Bowl of Hygieia), with the aim of investigating possible fraud regarding the litigation of 
drugs for rare diseases, including Soliris,eculizumab’s trade nameb. That same year, the 
MS undertook the auditing of the drug purchasing process. Of the 414 people who had 
court decisions to receive the drug in 2017, 28 were not located; five did not reside at the 
informed address; six refused to provide information; and 13 had already passed away. 
Graver still: about half of the patients did not present evidence of diagnosis of the disease 
and, still had been receiving eculizumab by court decisionc.
On the other hand, in terms of the number of purchases and quantities, growth resumed 
in 2018, and the year accounted for 28.2% of the total number of dosage forms acquired 
over the period. Part of this increase may be a backlash to the already mentioned drop in 
2017, since it is a chronic drug that is used for life. It is also not uncommon after the broad 
disclosure of the drug’s market approval to induce an increase in prescribing, in this case still 
under the aegis of litigation, since the drug had not been included in the SUS funding list. 
This inclusion only occurred at the end of December 2018 and, until the date of manuscript 
preparation, the drug awaited the development of a clinical protocol by the MS to be 
regularly provided to patients. Over the years studied and even without the presence of 
an active market license until March 2017, the access to the drug has always occurred 
via legal demands, in individual actions that have been responsible for extremely 
significant expenditures. 
The literature shows many examples of how litigation has been used as a strategy to 
access unlicensed drugs in Brazil20–22. Evidence suggests that pharmaceutical companies 
may use relationships with patient advocacy groups and health professionals to expand 
market share by litigation, eventually forcing the incorporation of the drug into the health 
system23,24. A study of 514 lawsuits that demanded the drug and had the MS as a defendant, 
between 2010 and 2016, showed that 376 (73%) originated in the Federal District and 46 
(9%) in the state of São Paulo. Only a single law firm was responsible for 361 lawsuits (70%). 
The proportions of prescriptions originating from private physicians and SUS are similar 
b Reuters. PF investiga fraude 
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de 2017. [citado 28 mar 2019]. 
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e Insumos Estratégicos, 
Departamento do Complexo 
Industrial e Inovação em Saúde. 
Propostas de Projeto de Parcerias 
para o Desenvolvimento 
Produtivo não aprovadas. 
Brasília, DF; 2017 [citado 4 abr 
2019]. Disponível em: http://
portalarquivos2.saude.gov.br/
images/pdf/2018/junho/18/
Propostas-de-projeto-de-PDP-
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(respectively, 32.4% and 31.2%), drawing attention to the fact that in 27.1% of the lawsuits 
there was no record of the prescriber’s name25.
Eculizumab is considered an “orphan drug”, which gives it a set of specificities in terms 
of sanitary licensing, prices, and access for payment or reimbursement by health systems. 
The designation of “orphan” is associated with drugs developed for the treatment of 
diseases that would presumably provide little economic return on investment in research 
and development (R&D) made by the pharmaceutical industry or patent holders. Low 
profitability may be due to the low prevalence or incidence of the disease in a population, 
which would make the drug market small and unprofitable, or to therapeutic focus for 
prevalent conditions in less developed countries devoid of resources for payment of the price 
that would represent profit for the industry. As a result, many legislations were successively 
created in the United States (1983), Japan (1993), Australia (1998), and Europe (2000) to 
encourage the development of orphan drugs26. 
The high price paid for eculizumab by the MS and its variation over time draws attention. Use 
directed to a rare disease is often reported as a reason for the high price of the drug, with the 
justification that it incurs R&D costs similar to those aimed at common diseases, but with 
fewer potential users to ensure the return on investments. However, this justification has 
been questioned. The sale of drugs for rare diseases has sometimes become more profitable 
than traditional drugs because of the granting of various government benefits, such as 
market exclusivity for longer periods, tax incentives, economic support for the development 
of specific research, and market approval in a shorter timeframe and with less demanding 
scientific evidence criteria26–28. 
However, the cost of clinical trials for “orphan drugs” is much lower than for drugs for other 
diseases, since the number of patients involved is much smaller. Small clinical studies 
and absence of alternative treatments put these “orphan drugs” to the advantage when 
submitted to regulatory reviews. Few patients and lack of competition also determine 
the need for lower investments in marketing. Moreover, given their high cost, these 
drugs are generally funded by governments or insurers29. As a result, pharmaceutical 
companies with authorization to market orphan products can be more profitable than 
those without this type of product in their portfolios. Between 2000 and 2012, companies 
that sold “orphan drugs” had a return on investment 9.6% higher than manufacturers of 
“non-orphaned” drugs30.
The request for market approval of a drug in Brazil and, subsequently, the request for pricing 
by CMED are exclusively manufacturer attributions. Until 2017, the absence of market 
approval and price determined that the Brazilian Ministry of Health was obliged to import 
it at any price charged by the supplier, burdened by the entire transport and distribution 
costs to meet the lawsuit demand for eculizumab.  
Although the drug was the subject of purchases to meet litigation demands for a long 
time, the company did not request market approval in the country for almost nine years 
after its introduction in American and European markets, even considering the size of the 
Brazilian population and the prioritization of analysis given by ANVISA to drugs for rare 
diseases31. The drug was only registered in 2015, when the patent protection of eculizumab 
coincidentally expired in the country.
Without market approval there was no established price for sale to the government and 
it could not be submitted to assessment by Conitec. But it continued to be purchased to 
treat few patients via litigation, always at high prices, and with bidding waiver. In other 
words, until 2015 the company’s profit was assured since the producer fully defined and 
controlled the sales prices.
These aspects clarify the effect of market approval on the verified price reduction, greater 
than 35% in 2017, and the maintenance of this decrease also in 2018, even if at a smaller 
level. This was not a consequence of incorporation by Conitec which only took place in 
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December 2018; incorporation supposedly schedules needs and acquisitions, allowing for 
regular and centralized purchases, economies of scale, and the use of state purchasing 
power for negotiations and lower prices32. Major drops may still occur since one of the 
explicit conditions in the decision to incorporate the drug into SUS is the “negotiation for 
significant price reduction”7. 
Another factor with future reducing impact potential is the possibility of establishing a 
productive development partnership (PDP) for technological transfer and local production, 
since the drug is no longer under patent. On this regard, it is noteworthy that eculizumab 
was part of the annual list of strategic products for SUS, with a view to the formation 
of a PDP published in the MS Ordinance, no. 704, March 201733. However, the drug does 
not appear in the MS/GM Ordinance no. 731, March 26, 2018,34 which presents the list 
of approved projects, or in the list of approved PDP proposals made available on the 
DECEIIS/SCTIEd page, leading to the assumption that no proposals were submitted by 
interested companies. 
Although a drop in lawsuits is expected after the incorporation into the SUS, this will 
not necessarily occur. Incorporation establishes an official market, however, with lower 
prices than those practiced in litigation and only for the defined indication (PNH). It is still 
possible to appeal to the judicial route for cases that do not meet the criteria shown in the 
clinical protocol, as well as for other registered (aHUS) and unregistered indications in the 
country,35,36 keeping this profit filter alive for the company. Monitoring of purchases and of 
prices may be useful to better clarify future behavior regarding this drug.
The estimated utilization values were independently estimated (inferred by the number 
of potential treatments or estimated by DDD/1,000 inhabitants/year) and are consistent, 
with a progressive trend of growth over time. There are no international DDD utilization 
data but estimates will allow comparability over time37. The requirements for patient care 
and treatment only in Brazilian National Clinical Research Network hospitals and the 
mandatory recording of clinical and pharmaceutical data in the SUS may bring forth more 
reliable utilization information7.
This study has some limitations. Although SIASG shows contracted purchase data and not 
finalized purchases, it is reasonable to assume that, in the case of drugs purchased for legal 
demands, these purchases would have been made effective. The aggregated data shown 
in SIASG also do not show the number of treated patients or of new patients treated each 
year, the indications of treatment underlying purchases from litigation or the expansion 
of post-incorporation coverage. Finally, the research interval fails to identify the impact 
of incorporation, which occurred at the end of the studied period in respect to quantities 
and prices.
The growth of purchased volumes indicates expansion of eculizumab use over time. The high 
associated expenditures have a significant financial impact on the provision of drugs by the 
Brazilian Ministry of Health, especially because until the end of 2018 100% of access to the 
drug was linked to litigation. Furthermore, the price variation before market approval also 
reinforces the importance of the licensing requirement for manufacturers who wish to sell 
drugs in the domestic market. Finally, the study shows the need for permanent monitoring 
and auditing of drug purchases to meet lawsuits, especially those for high-cost drugs. 
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